These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 24460250)

  • 21. Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.
    Distler E; Albrecht J; Brunk A; Khan S; Schnürer E; Frey M; Mottok A; Jordán-Garrote AL; Brede C; Beilhack A; Mades A; Tomsitz D; Theobald M; Herr W; Hartwig UF
    Int J Cancer; 2016 Mar; 138(5):1256-68. PubMed ID: 26376181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High ALDHdim-expressing CD34+CD38- cells in leukapheresed peripheral blood is a reliable guide for a successful leukemic xenograft model of acute myeloid leukemia.
    Lee JY; Park S; Han AR; Lim J; Min WS; Kim HJ
    Oncol Rep; 2014 Oct; 32(4):1638-46. PubMed ID: 25069538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.
    Heydt Q; Larrue C; Saland E; Bertoli S; Sarry JE; Besson A; Manenti S; Joffre C; Mansat-De Mas V
    Oncogene; 2018 Feb; 37(6):787-797. PubMed ID: 29059168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2Rcγnull mice reflects individual leukemogenecity and highly correlates with clinical outcome.
    Woiterski J; Ebinger M; Witte KE; Goecke B; Heininger V; Philippek M; Bonin M; Schrauder A; Röttgers S; Herr W; Lang P; Handgretinger R; Hartwig UF; André MC
    Int J Cancer; 2013 Oct; 133(7):1547-56. PubMed ID: 23526331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo.
    Yang L; Weng W; Sun ZX; Fu XJ; Ma J; Zhuang WF
    Biochem Biophys Res Commun; 2015 May; 460(4):903-8. PubMed ID: 25824043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Improved Protocol for Establishment of AML Patient-Derived Xenograft Models.
    Hassan N; Yang J; Wang JY
    STAR Protoc; 2020 Dec; 1(3):100156. PubMed ID: 33377050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
    Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
    Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HES1 activation suppresses proliferation of leukemia cells in acute myeloid leukemia.
    Tian C; Yu Y; Jia Y; Zhu L; Zhang Y
    Ann Hematol; 2015 Sep; 94(9):1477-83. PubMed ID: 26092281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth of primary human acute lymphoblastic and myeloblastic leukemia in SCID mice.
    De Lord C; Clutterbuck R; Powles R; Morilla R; Hanby A; Titley J; Min T; Millar J
    Leuk Lymphoma; 1994 Dec; 16(1-2):157-65. PubMed ID: 7696922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model.
    Uesato N; Fukui K; Maruhashi J; Tojo A; Tajima N
    Exp Hematol; 2006 Oct; 34(10):1385-92. PubMed ID: 16982331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic heterogeneity in acute leukemia.
    Paulsson K
    Cytogenet Genome Res; 2013; 139(3):174-80. PubMed ID: 23363651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
    Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors.
    Feuring-Buske M; Gerhard B; Cashman J; Humphries RK; Eaves CJ; Hogge DE
    Leukemia; 2003 Apr; 17(4):760-3. PubMed ID: 12682634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conditions for engraftment of human acute myeloid leukemia (AML) in SCID mice.
    Terpstra W; Prins A; Visser T; Wognum B; Wagemaker G; Löwenberg B; Wielenga J
    Leukemia; 1995 Sep; 9(9):1573-7. PubMed ID: 7658726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human AML cells in NOD/SCID mice: engraftment potential and gene expression.
    Lumkul R; Gorin NC; Malehorn MT; Hoehn GT; Zheng R; Baldwin B; Small D; Gore S; Smith D; Meltzer PS; Civin CI
    Leukemia; 2002 Sep; 16(9):1818-26. PubMed ID: 12200698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
    Kenderian SS; Ruella M; Shestova O; Klichinsky M; Aikawa V; Morrissette JJ; Scholler J; Song D; Porter DL; Carroll M; June CH; Gill S
    Leukemia; 2015 Aug; 29(8):1637-47. PubMed ID: 25721896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
    Fan D; Li Z; Zhang X; Yang Y; Yuan X; Zhang X; Yang M; Zhang Y; Xiong D
    J Hematol Oncol; 2015 Feb; 8():18. PubMed ID: 25879549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.
    Lee EM; Yee D; Busfield SJ; McManus JF; Cummings N; Vairo G; Wei A; Ramshaw HS; Powell JA; Lopez AF; Lewis ID; McCall MN; Lock RB
    Haematologica; 2015 Jul; 100(7):914-26. PubMed ID: 26130514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.